Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1253MR)

This product GTTS-WQ1253MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1253MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8621MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ11683MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ8093MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ2821MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ13113MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ12123MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ15097MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ10616MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW